Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Caribou Biosciences Q3 2026 Results: Net Loss of $26.6M, Loss Narrows

Caribou Biosciences reported a net loss of $76.0 million for the nine months ended September 30, 2026, compared to $121.6 million in the prior year period. Total assets decreased to $123.0 million from $175.4 million at year-end 2025, while the company raised $22.8 million in net proceeds through an at-the-market (ATM) offering during the first nine months of 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.62.2
Net income-26.6-27.5
EPS (diluted, $ a share)$-0.25$-0.30

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-26.9%
Source

10-Q filed with the SEC, NASDAQ: CRBU. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Caribou Biosciences, Inc.: key numbers

Share price
$0.3407Close, Nov 17
Market cap
$36.8M
Shares outstanding
108.04MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Caribou Biosciences, Inc.

All →
4:11 PM ET 8-K
Financial Results

Caribou Biosciences Financial Results

Caribou Biosciences reported Q3 2026 financial results, including a GAAP net loss of $26.6 million on revenue of $1.6 million. The company also highlighted its October 2026 decision to discontinue clinical trials for vispa-cel and CB-011 and reduce its workforce while exploring strategic alternatives such as a merger or acquisition.

Term
Q3 2026
4:07 PM ET 8-K
Business Update

Caribou Biosciences Business Update

Caribou Biosciences is exploring strategic alternatives and implementing a restructuring plan that includes discontinuing its allogeneic CAR-T cell therapy programs, vispa-cel and CB-011. The company is conducting a substantial workforce reduction and expects to incur restructuring charges between $15 million and $19 million, primarily for severance and clinical trial wind-down costs.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.